Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies.

Autor:	Thompson MA; Aurora Cancer Care, Advocate Aurora Health, Milwaukee, WI., Hallmeyer S; Hematology/Oncology, Advocate Aurora Health, Downers Grove, IL., Fitzpatrick VE; Advocate Aurora Research Institute, Advocate Aurora Health, Downers Grove, IL., Liao Y; Advocate Aurora Research Institute, Advocate Aurora Health, Downers Grove, IL., Mullane MP; Aurora Cancer Care, Advocate Aurora Health, Milwaukee, WI., Medlin SC; Aurora Cancer Care, Advocate Aurora Health, Milwaukee, WI., Copeland K; ACL Laboratories, Advocate Aurora Health, West Allis, WI., Weese JL; Aurora Cancer Care, Advocate Aurora Health, Milwaukee, WI.; Hematology/Oncology, Advocate Aurora Health, Downers Grove, IL.
Jazyk:	angličtina
Zdroj:	Journal of patient-centered research and reviews [J Patient Cent Res Rev] 2022 Jul 18; Vol. 9 (3), pp. 149-157. Date of Electronic Publication: 2022 Jul 18 (Print Publication: 2022).
DOI:	10.17294/2330-0698.1952
Abstrakt:	Purpose: This study sought to describe the changes in immune response to a third dose of either Pfizer's or Moderna's COVID-19 mRNA vaccine (3V) among patients with hematologic malignancies, as well as associated characteristics. Methods: This retrospective cohort study analyzed pre-3V and post-3V data on 493 patients diagnosed with hematologic malignancies across a large Midwestern health system between August 28, 2021, and November 1, 2021. For antibody testing, S1 spike antigen of the SARS-CoV-2 virus titer was used to determine serostatus. Results: Among 493 participants, 274 (55.6%) were seropositive both pre- and post-3V (+/+) while 115 (23.3%) seroconverted to positive from prior negative following the third dose (-/+). The remaining 104 (21.1%) were seronegative both before and after 3V (-/-). No participant was seropositive pre-3V and seronegative post-3V (+/-). Results showed a statistically significant increase in the proportion of seropositivity after receiving a third COVID-19 vaccine (P<0.00001). Response to 3V was significantly associated with the 3V vaccine type (P=0.0006), previous COVID-19 infection (P=0.0453), and malignancy diagnosis (P<0.0001). Likelihood of seroconversion (-/+) after 3V was higher in the group of patients with multiple myeloma or related disorders compared to patients with lymphoid leukemias (odds ratio: 8.22, 95% CI: 2.12-31.79; P=0.0008). Conclusions: A third COVID-19 vaccination is effective in producing measurable seroconversion in many patients with hematologic malignancies. Oncologists should actively encourage all their patients, especially those with multiple myeloma, to receive a 3V, given the high likelihood of seroconversion. Competing Interests: Conflicts of Interest None. (© 2022 Aurora Health Care, Inc.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu